Owners, management and financials
CVR: 36699051
Secondary names: Pharmamentum ApS, Pharmanovia Denmark ApS
Previous names: Pharmamentum ApS
EUR 52,583,756
Revenue
Net result: EUR 12,487
Atnahs Pharma UK Limited (100%)
CVR · view owners
Christoph Michael Habereder
Board: Mohammad Muqtadir Samy (chair) and 2 members
CVR · view management
Active
Founded 27 March 2015
CVR · view overview
0 employees
Annual report 2026 · average
Director role ended: Neeshe Bhikhubhai Williams
CVR · 09/06/2026
View the full event history
Atnahs Pharma Denmark ApS is a Danish company of the type Anpartsselskab based in København S, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Pharmamentum ApS. The management consists of Christoph Michael Habereder. The board consists of Mohammad Muqtadir Samy (chair), Christoph Michael Habereder and Twan Johannes Anna Nouwen. The company is owned by Atnahs Pharma UK Limited. According to the 2026 annual report, the company had an average of 0 employees. In 2026, the company reported revenue of EUR 52,583,756 and a net result of EUR 12,487 compared with DKK 47,843 the year before. Equity in the 2026 report amounted to EUR 2,094,136.
Source: annual report 2026, Danish Business Authority
The financial health of Atnahs Pharma Denmark ApS shows signs of volatility, particularly with fluctuating revenues and profitability. In 2026, the company reported revenue of €52.58 million but experienced a gross loss of €1.6 million, indicating challenges in maintaining healthy margins. The trend from 2023 to 2026 reveals a decline in revenue from DKK 517.23 million to €52.58 million, alongside a drop in gross profit, raising concerns about operational efficiency. However, equity has remained relatively stable, increasing from DKK 142,279 in 2022 to €2.09 million in 2026, suggesting some resilience. Positioned within the pharmaceutical wholesale industry, Atnahs Pharma faces significant challenges in profitability and margin management, which could impact its competitive standing.
AI-generated summary · Generated 01/10/2026
Selskabets formål er at drive handelsvirksomhed med farmaceutiske produkter, herunder udvikling, salg, distribution og markedsføring af farmaceutiske produkter og dermed beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202601/04/2025 – 31/03/2026 | 52.6 mio. EUR | 12 t. EUR | 33.1 mio. EUR | 2.1 mio. EUR | 0 | |
| 202501/04/2024 – 31/03/2025 | 71.4 mio. | 48 t. | 51.2 mio. | 2.1 mio. | 0 | |
| 202401/04/2023 – 31/03/2024 | 91.3 mio. EUR | 20 t. EUR | 67 mio. EUR | 2 mio. EUR | - | |
| 202301/04/2022 – 31/03/2023 | 517.2 mio. | 14.7 mio. | 407.3 mio. | 14.9 mio. | - | |
| 202201/04/2021 – 31/03/2022 | - | 3.6 mio. | 202.9 mio. | 142 t. | - | |
| 202101/04/2020 – 31/03/2021 | - | 275 t. | 127.9 mio. | -3.5 mio. | - | |
| 202001/04/2019 – 31/03/2020 | - | -1.4 mio. | 3.9 mio. | -3.8 mio. | - | |
| 201901/04/2018 – 31/03/2019 | - | -1.1 mio. | 1.2 mio. | -2.4 mio. | - | |
| 201801/04/2017 – 31/03/2018 | - | -1.9 mio. | 7.2 mio. | -1.3 mio. | - |
Compared to 405 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of Atnahs Pharma Denmark ApS is 36699051.
Atnahs Pharma Denmark ApS is owned by Atnahs Pharma UK Limited.
The management of Atnahs Pharma Denmark ApS consists of Christoph Michael Habereder.
The board of Atnahs Pharma Denmark ApS consists of Mohammad Muqtadir Samy, Christoph Michael Habereder and Twan Johannes Anna Nouwen, with Mohammad Muqtadir Samy as chair.
In 2026, Atnahs Pharma Denmark ApS reported revenue of EUR 52,583,756.
Atnahs Pharma Denmark ApS had an average of 0 employees in the 2026 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Atnahs Pharma Denmark ApS has published its annual report for 2026. Revenue came to DKK 52,583,756, and the net result was DKK 12,487.
As of June 9, 2026, Neeshe Bhikhubhai Williams has left the board of directors of Atnahs Pharma Denmark ApS.
As of June 9, 2026, Christoph Michael Habereder is registered as director of Atnahs Pharma Denmark ApS.
As of June 9, 2026, Neeshe Bhikhubhai Williams has stepped down as director of Atnahs Pharma Denmark ApS.
As of March 24, 2026, Mohammad Muqtadir Samy has joined the board of directors of Atnahs Pharma Denmark ApS.
As of March 24, 2026, Amit Vijaykumar Patel has left the board of directors of Atnahs Pharma Denmark ApS.
As of March 23, 2026, Mohammad Muqtadir Samy has left the board of directors of Atnahs Pharma Denmark ApS.
As of February 17, 2026, Twan Johannes Anna Nouwen has joined the board of directors of Atnahs Pharma Denmark ApS.
As of February 17, 2026, Mohammad Muqtadir Samy has joined the board of directors of Atnahs Pharma Denmark ApS.
As of February 17, 2026, Christoph Michael Habereder has joined the board of directors of Atnahs Pharma Denmark ApS.
As of February 17, 2026, Santsagar Patel has left the board of directors of Atnahs Pharma Denmark ApS.
As of November 26, 2025, CHRISTENSEN KJÆRULFF STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of Atnahs Pharma Denmark ApS.
As of November 26, 2025, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Atnahs Pharma Denmark ApS.
Atnahs Pharma Denmark ApS has published its annual report for 2025. Revenue came to DKK 71,428,252, and the net result was DKK 47,843.
As of September 30, 2025, James Sang Bum Lee has left the board of directors of Atnahs Pharma Denmark ApS.
As of September 30, 2025, Zubair Javeed has left the board of directors of Atnahs Pharma Denmark ApS.
As of September 30, 2025, Neeshe Bhikhubhai Williams is registered as director of Atnahs Pharma Denmark ApS.
As of September 30, 2025, James Sang Bum Lee has stepped down as director of Atnahs Pharma Denmark ApS.
As of August 25, 2025, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Atnahs Pharma Denmark ApS.
As of August 19, 2025, KPMG P/S has stepped down as auditor of Atnahs Pharma Denmark ApS.
As of May 1, 2025, Santsagar Patel has joined the board of directors of Atnahs Pharma Denmark ApS.
As of May 1, 2025, Zubair Javeed has joined the board of directors of Atnahs Pharma Denmark ApS.
As of May 1, 2025, James Charles Burt has left the board of directors of Atnahs Pharma Denmark ApS.
Atnahs Pharma Denmark ApS has published its annual report for 2024. Revenue came to DKK 91,292,078, and the net result was DKK 20,450.
Atnahs Pharma Denmark ApS has published its annual report for 2023. Revenue came to DKK 517,225,669, and the net result was DKK 14,720,135.
As of October 6, 2023, Jesper Wilhelm Voss has left the board of directors of Atnahs Pharma Denmark ApS.
As of October 6, 2023, James Sang Bum Lee is registered as director of Atnahs Pharma Denmark ApS.
As of October 6, 2023, Amit Vijaykumar Patel has stepped down as director of Atnahs Pharma Denmark ApS.
As of May 24, 2023, James Sang Bum Lee has joined the board of directors of Atnahs Pharma Denmark ApS.
As of May 24, 2023, Felipe Andres Florez Arango has left the board of directors of Atnahs Pharma Denmark ApS.
Atnahs Pharma Denmark ApS has published its annual report for 2022. Gross profit came to DKK 9,761,758, and the net result was DKK 3,647,068.
As of March 29, 2022, Rishi Bhikhu has left the board of directors of Atnahs Pharma Denmark ApS.
As of December 17, 2021, James Charles Burt has joined the board of directors of Atnahs Pharma Denmark ApS.
As of December 17, 2021, Alastair Thomas Badgett Hay has left the board of directors of Atnahs Pharma Denmark ApS.
Atnahs Pharma Denmark ApS has published its annual report for 2021. Gross profit came to DKK 5,092,802, and the net result was DKK 275,303.
As of June 16, 2021, Felipe Andres Florez Arango has joined the board of directors of Atnahs Pharma Denmark ApS.
As of February 10, 2021, Jesper Wilhelm Voss has joined the board of directors of Atnahs Pharma Denmark ApS.
As of February 10, 2021, Svend Aage Johansen has left the board of directors of Atnahs Pharma Denmark ApS.
Atnahs Pharma Denmark ApS has published its annual report for 2020. Gross profit came to DKK -1,258,513, and the net result was DKK -1,418,130.
As of February 24, 2020, Anthony Charles Playle has left the board of directors of Atnahs Pharma Denmark ApS.
Atnahs Pharma Denmark ApS has published its annual report for 2019. Gross profit came to DKK 778,878, and the net result was DKK -1,052,467.
As of August 7, 2019, Svend Aage Johansen has joined the board of directors of Atnahs Pharma Denmark ApS.
As of August 7, 2019, Neeshe Bhikhubhai Williams has joined the board of directors of Atnahs Pharma Denmark ApS.
As of August 7, 2019, Rishi Bhikhu has joined the board of directors of Atnahs Pharma Denmark ApS.
As of August 7, 2019, Alastair Thomas Badgett Hay has joined the board of directors of Atnahs Pharma Denmark ApS.
As of August 7, 2019, Dipen Vijaykumar Patel has left the board of directors of Atnahs Pharma Denmark ApS.
As of August 7, 2019, Mark John Cotterill has left the board of directors of Atnahs Pharma Denmark ApS.
As of February 28, 2019, Mark John Cotterill has joined the board of directors of Atnahs Pharma Denmark ApS.
As of February 28, 2019, Svend Aage Johansen has left the board of directors of Atnahs Pharma Denmark ApS.
As of February 28, 2019, Amit Vijaykumar Patel is registered as director of Atnahs Pharma Denmark ApS.
As of February 28, 2019, Svend Aage Johansen has stepped down as director of Atnahs Pharma Denmark ApS.
On January 15, 2019, the company changed its name from Pharmamentum ApS to Atnahs Pharma Denmark ApS.
Atnahs Pharma Denmark ApS has published its annual report for 2018. Gross profit came to DKK -1,427,823, and the net result was DKK -1,858,350.
As of February 28, 2018, is registered as an owner of Atnahs Pharma Denmark ApS with an ownership share of 100%.
Atnahs Pharma Denmark ApS has published its interim report for the period January 1, 2016 to March 31, 2017.
Atnahs Pharma Denmark ApS has published its interim report for the period March 27, 2015 to December 31, 2015.
As of April 20, 2016, KPMG P/S has been appointed auditor of Atnahs Pharma Denmark ApS.
As of March 31, 2016, Svend Aage Johansen has joined the board of directors of Atnahs Pharma Denmark ApS.
As of March 31, 2016, Amit Vijaykumar Patel has joined the board of directors of Atnahs Pharma Denmark ApS.
As of March 31, 2016, Dipen Vijaykumar Patel has joined the board of directors of Atnahs Pharma Denmark ApS.
As of March 31, 2016, Anthony Charles Playle has joined the board of directors of Atnahs Pharma Denmark ApS.
As of March 31, 2016, Svend Aage Johansen is registered as director of Atnahs Pharma Denmark ApS.
As of March 31, 2016, Lisbet Johansen has stepped down as director of Atnahs Pharma Denmark ApS.
As of March 27, 2015, Lisbet Johansen is registered as director of Atnahs Pharma Denmark ApS.
Atnahs Pharma Denmark ApS was founded on March 27, 2015.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Companies in the same industry and area
CVR 39371049
CVR 39503778
CVR 40873309
CVR 31774284
CVR 37285145
